Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US-9096651-B2 · Aug 4, 2015 · US
Composition for prophylaxis or treatment of IL-8 related diseases
US12516115B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12516115-B2 |
| Application number | US-202318450863-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 16, 2023 |
| Priority date | Aug 5, 2016 |
| Publication date | Jan 6, 2026 |
| Grant date | Jan 6, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.
First claim
Opening claim text (preview).
The invention claimed is: 1 . A method of inhibiting IL-8, which comprises administering an anti-IL-8 antibody that binds to human IL-8 to a subject in need thereof, wherein the subject suffers from an IL-8-related disease selected from the group consisting of chronic obstructive pulmonary disease (COPD), cystic fibrosis, psoriasis, hepatic fibrosis, renal fibrosis, and pulmonary fibrosis, and wherein the anti-IL-8 antibody comprises: (a) the amino acid sequence of SEQ ID NO: 23 as HVR-H1, (b) the amino acid sequence of SEQ ID NO: 29 as HVR-H2, (c) the amino acid sequence of SEQ ID NO: 30 as HVR-H3, (d) the amino acid sequence of SEQ ID NO: 26 as HVR-L1, (e) the amino acid sequence of SEQ ID NO: 31 as HVR-L2, and (f) the amino acid sequence of SEQ ID NO: 32 as HVR-L3. 2 . The method of claim 1 , wherein the anti-IL-8 antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 34 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 35. 3 . The method of claim 2 , wherein the anti-IL-8 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 36 and a light chain comprising the amino acid sequence of SEQ ID NO: 38. 4 . The method of claim 2 , wherein the anti-IL-8 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 37 and a light chain comprising the amino acid sequence of SEQ ID NO: 38. 5 . The method of claim 1 , wherein the disease is COPD. 6 . The method of claim 1 , wherein the disease is cystic fibrosis. 7 . The method of claim 1 , wherein the disease is psoriasis. 8 . The method of claim 1 , wherein the disease is hepatic fibrosis. 9 . The method of claim 1 , wherein the disease is renal fibrosis. 10 . The method of claim 1 , wherein the disease is pulmonary fibrosis. 11 . The method of claim 2 , wherein the disease is COPD. 12 . The method of claim 2 , wherein the disease is cystic fibrosis. 13 . The method of claim 2 , wherein the disease is psoriasis. 14 . The method of claim 2 , wherein the disease is hepatic fibrosis. 15 . The method of claim 2 , wherein the disease is renal fibrosis. 16 . The method of claim 2 , wherein the disease is pulmonary fibrosis.
Assignees
Inventors
Classifications
Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Framework region [FR] · CPC title
Complementarity determining region [CDR] · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12516115B2 cover?
- For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.
- Who is the assignee on this patent?
- Chugai Pharmaceutical Co Ltd, Univ Jichi Medical, Nat Inst Biomedical Innovation Health & Nutrition
- What technology area does this patent fall under?
- Primary CPC classification A61K39/395. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).